Characterization of Novel Piperidine-Based Inhibitor of Cathepsin B-Dependent Bacterial Toxins and Viruses

ACS Infectious Diseases
Stella HartmannMikhail Martchenko

Abstract

Exploiting the host endocytic trafficking pathway is a common mechanism by which bacterial exotoxins gain entry to exert virulent effects upon the host cells. A previous study identified a small-molecule, 1-(2,6-dimethyl-1-piperidinyl)-3-[(2-isopropyl-5-methylcyclohexyl)oxy]-2-propanol, that blocks the process of anthrax lethal toxin (LT) cytotoxicity. Here, we report the characterization of the bioactivity of this compound, which we named RC1. We found that RC1 protected host cells independently of LT concentration and also blocked intoxication by other bacterial exotoxins, suggesting that the target of the compound is a host factor. Using the anthrax LT intoxication pathway as a reference, we show that while anthrax toxin is able to bind to cells and establish an endosomal pore in the presence of the drug, the toxin is unable to translocate into the cytosol. We demonstrate that RC1 does not inhibit the toxin directly but rather reduces the enzymatic activity of host cathepsin B that mediates the escape of toxins into the cytoplasm from late endosomes. We demonstrate that the pathogenicity of Human cytomegalovirus and Herpes simplex virus 1, which relies on cathepsin B protease activity, is reduced by RC1. This study reveals t...Continue Reading

References

Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E J BowmanK Altendorf
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·S R BlankeR J Collier
Jul 20, 1999·Annual Review of Biophysics and Biomolecular Structure·M E McGrath
Aug 11, 1999·Biochemistry·C J MillerR J Collier
Mar 29, 2000·Protein Expression and Purification·S Park, S H Leppla
Dec 9, 2000·International Journal of Medical Microbiology : IJMM·R PellizzariC Montecucco
Nov 9, 2001·Nature·K A BradleyJ A Young
Jan 29, 2003·The Journal of Cell Biology·Laurence AbramiF Gisou van der Goot
Apr 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Heather M ScobieJohn A T Young
Jan 14, 2004·Nature Structural & Molecular Biology·Rekha G PanchalSina Bavari
Feb 1, 2005·Trends in Microbiology·Laurence AbramiF Gisou van der Goot
May 20, 2005·Gene Therapy·L Johannes, D Decaudin
Jun 15, 2005·Cellular Microbiology·Lina GuerraTeresa Frisan
Sep 6, 2005·Proceedings of the National Academy of Sciences of the United States of America·G Jonah A RaineyJohn A T Young
Mar 6, 2007·Annual Review of Biochemistry·John A T Young, R John Collier
Jul 20, 2007·Nature Reviews. Molecular Cell Biology·J Paul LuzioNicholas A Bright
Mar 26, 2008·Nature Reviews. Immunology·Jenny P-Y TingDaniel T Bergstralh
May 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Li-Chung HsuMichael Karin
Jul 25, 2009·Journal of Molecular Biology·Alexander F KintzerBryan A Krantz
Aug 24, 2010·Recent Patents on CNS Drug Discovery·Lindsay H Burns, Hoau-Yan Wang
Mar 16, 2013·Protein Science : a Publication of the Protein Society·E P GogolM T Fisher
Nov 6, 2013·Proceedings of the National Academy of Sciences of the United States of America·Eugene J GillespieKenneth A Bradley
Apr 9, 2014·Bioarchitecture·Volney L Sheen
Jun 10, 2015·Annals of Clinical Microbiology and Antimicrobials·Kevin KimMikhail Martchenko
Aug 28, 2015·Scientific Reports·Leeor ZilbermintzMikhail Martchenko
Mar 14, 2017·Expert Review of Anti-infective Therapy·Cristiano SalataGiorgio Palù

❮ Previous
Next ❯

Citations

Oct 26, 2018·ACS Infectious Diseases·Stella HartmannMikhail Martchenko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.